Journal of Zhejiang University-SCIENCE B

, Volume 20, Issue 10, pp 849–860 | Cite as

Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation

  • Bing HaoEmail author
  • Song Gao
  • Yi-wen Sang
  • Lin Wang
  • Xue-qin Meng
  • Jing-ya You


We investigated the value of autoantibodies as biomarkers of chronic graft-versus-host disease (cGVHD) by analyzing the autoantibody profiles of 65 patients (34 cGVHD and 31 non-cGVHD) surviving longer than three months after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Autoantibodies to at least one antigen were detected in 45 patients (70.8%), with multiple autoantibodies detected in 30 patients (46.2%). Antinuclear antibodies (ANAs) were the most frequently detected autoantibodies, with a significantly higher prevalence in non-cGVHD patients and cGVHD patients than that in healthy controls (HCs). ANA-nucleolar (ANA-N) was the main immunofluorescence pattern of ANA-positivity in both the non-cGVHD and cGVHD groups. There was a higher prevalence of anti-Ro52-positivity in non-cGVHD and cGVHD patients than in HC. Liver cGVHD was significantly associated with anti-Ro52-positivity. However, cGVHD activity and severity were not associated with the presence of autoantibodies. Similarly, there were no significant differences in overall survival or relapse among the four groups of patients expressing autoantibodies. Our results suggest that autoantibodies have limited value in predicting cGVHD.

Key words

Autoantibody Chronic graft-versus-host disease (cGVHD) Anti-Ro52 



目 的

通过检测慢性移植物抗宿主病 (cGVHD) 病人血清中自身抗体的表达来发现和鉴定新的用于诊断和疾病监测的标志物。


我们创新性地应用了包含核仁形成区抗原成分的自身抗体谱对各实验组进行了超过 30 种自身抗体的筛查, 首次发现 anti-Ro52 抗体可能与肝脏 cGVHD 有关。

方 法

联合应用间接免疫荧光、 线性免疫印迹和酶联免疫吸附试验 (ELISA)对各实验组进行自身抗体 谱筛查, 采用统计学软件对实验结果和临床数据进行比对分析。

结 论

我们的研究证实异基因造血干细胞移植后各组病人都可能出现以核仁型抗核抗体 (ANA) 为主的自身抗体表达增高, 并且 anti-Ro52 抗体在肝脏 cGVHD 病人血清中显著增高, 然而自身抗体与 cGVHD 的活动性、 严重程度和预后均无明显相关性。 我们的研究结果表明, 自身抗体在预测 cGVHD 方面的价值有限。


自身抗体 慢性移植物抗宿主病 (cGVHD) Anti-Ro52 

CLC number



Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



Bing HAO and Song GAO performed the experimental research and data analysis, and wrote and edited the manuscript. Yi-wen SANG and Lin WANG performed the data analysis. Xue-qin MENG and Jing-ya YOU contributed to the ELISA assay. All authors have read and approved the final manuscript. Therefore, all authors have full access to all the data in the study and take responsibility for the integrity and security of the data.

Compliance with ethics guidelines

Bing HAO, Song GAO, Yi-wen SANG, Lin WANG, Xue-qin MENG, and Jing-ya YOU declare that they have no conflicts of interest.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study. Additional informed consent was obtained from all patients for whom identifying information is included in this article.


  1. Admou B, Essaadouni L, Amal S, et al., 2009. Autoantibodies in systemic sclerosis: clinical interest and diagnosis approach. Ann Biol Clin (Paris), 67(3):273–281. Google Scholar
  2. Anasetti C, Logan BR, Lee SJ, et al., 2012. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med, 367(16):1487–1496. CrossRefGoogle Scholar
  3. Arbuckle MR, McClain MT, Rubertone MV, et al., 2003. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med, 349(16): 1526–1533.
  4. Assandri R, Serana F, Montanelli A, 2017. Development of PBC/SSc overlap syndrome in chronic GVHD patient: immunological implications in the presence of mitochondrial, nucleolar and spindle midzone autoantigens. Gastroenterol Hepatol Bed Bench, 10(4):323–331.Google Scholar
  5. Bell SA, Faust H, Mittermüller J, et al., 1996. Specificity of antinuclear antibodies in scleroderma-like chronic graftversus- host disease: clinical correlation and histocompatibility locus antigen association. Br J Dermatol, 134(5): 848–854. CrossRefGoogle Scholar
  6. Catoggio LJ, Bernstein RM, Black CM, et al., 1983. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis, 42(1):23–27. CrossRefGoogle Scholar
  7. Chen GL, Arai S, Flowers MED, et al., 2011. A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood, 118(15):4070–4078. CrossRefGoogle Scholar
  8. Defendenti C, Atzeni F, Spina MF, et al., 2011. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev, 10(3):150–154. CrossRefGoogle Scholar
  9. Espinosa A, Dardalhon V, Brauner S, et al., 2009. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med, 206(8):1661–1671. CrossRefGoogle Scholar
  10. Filipovich AH, Weisdorf D, Pavletic S, et al., 2005. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant, 11(12):945–955. CrossRefGoogle Scholar
  11. Finkielman JD, Merkel PA, Schroeder D, et al., 2007. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med, 147(9):611–619. CrossRefGoogle Scholar
  12. Flynn R, Du J, Veenstra RG, et al., 2014. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood, 123(25): 3988–3998.
  13. Fraser CJ, Bhatia S, Ness K, et al., 2006. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the bone marrow transplant survivor study. Blood, 108(8): 2867–2873. CrossRefGoogle Scholar
  14. Fraticelli P, Gabrielli B, Pomponio G, et al., 2014. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther, 16(4):R144.
  15. Ho KT, Reveille JD, 2003. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther, 5(2):80–93. CrossRefGoogle Scholar
  16. Khanna D, Saggar R, Mayes MD, et al., 2011. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum, 63(11):3540–3546. CrossRefGoogle Scholar
  17. Kuzmina Z, Gounden V, Curtis L, et al., 2015. Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria. Am J Hematol, 90(2):114–119. CrossRefGoogle Scholar
  18. Langford CA, 2004. Antineutrophil cytoplasmic antibodies should not be used to guide treatment in Wegener’s granulomatosis. Clin Exp Rheumatol, 22(6 Suppl 36):S3-S6.Google Scholar
  19. Lee DH, Huh SJ, Yoon HH, et al., 2011. Clinical significance of anti-mitochondrial antibodies in a patient with chronic graft-versus-host disease following hematopoietic stem cell transplantation. Korean J Hematol, 46(3):200–202. CrossRefGoogle Scholar
  20. Lepelletier C, Bengoufa D, Lyes Z, et al., 2017. Dermatopulmonary syndrome associated with anti-MDA5 antibodies after allogeneic hematopoietic stem cell transplantation. JAMA Dermatol, 153(2):184–188. CrossRefGoogle Scholar
  21. Luo Y, Lai XY, Tan YM, et al., 2009. Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase. Leukemia, 23(6):1171–1174. CrossRefGoogle Scholar
  22. Maddison PJ, Skinner RP, Pereira RS, et al., 1986. Antinuclear antibodies in the relatives and spouses of patients with systemic sclerosis. Ann Rheum Dis, 45(10):793–799. CrossRefGoogle Scholar
  23. Miklos DB, Kim HT, Miller KH, et al., 2005. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood, 105(7):2973–2978. CrossRefGoogle Scholar
  24. Montano-Loza AJ, Shums Z, Norman GL, et al., 2012. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int, 32(1):85–92. CrossRefGoogle Scholar
  25. Moon JH, Lee SJ, Kim JG, et al., 2009. Clinical significance of autoantibody expression in allogeneic stem-cell recipients. Transplantation, 88(2):242–250. CrossRefGoogle Scholar
  26. Muro Y, Sugiura K, Morita Y, et al., 2008. High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus, 17(3):171–176. CrossRefGoogle Scholar
  27. Olivieri A, Locatelli F, Zecca M, et al., 2009. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood, 114(3):709–718. CrossRefGoogle Scholar
  28. Panoskaltsis-Mortari A, Tram KV, Price AP, et al., 2007. A new murine model for bronchiolitis obliterans post-bone marrow transplant. Am J Respir Crit Care Med, 176(7): 713–723.
  29. Patriarca F, Skert C, Sperotto A, et al., 2006. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol, 34(3):389–396. CrossRefGoogle Scholar
  30. Pidala J, Kurland B, Chai XY, et al., 2011. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood, 117(17):4651–4657. CrossRefGoogle Scholar
  31. Przepiorka D, Weisdorf D, Martin P, et al., 1995. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant, 15(6):825–828.Google Scholar
  32. Quaranta S, Shulman H, Ahmed A, et al., 1999. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin Immunol, 91(1): 106–116.
  33. Ruck S, Hilgendorf I, Müller-Hilke B, et al., 2008. Autoantibodymediated agranulocytosis in association with chronic GVHD. Bone Marrow Transplant, 42(5):359–360. CrossRefGoogle Scholar
  34. Sanz J, Arriaga F, Montesinos P, et al., 2007. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. Bone Marrow Transplant, 39(9):555–561. CrossRefGoogle Scholar
  35. Sarantopoulos S, Stevenson KE, Kim HT, et al., 2009. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood, 113(16):3865–3874. CrossRefGoogle Scholar
  36. Schulte-Pelkum J, Fritzler M, Mahler M, et al., 2009. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev, 8(7):632–637. CrossRefGoogle Scholar
  37. Sherer Y, Shoenfeld Y, 1998. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant, 22(9):873–881. CrossRefGoogle Scholar
  38. Sinico RA, Radice A, Corace C, et al., 2005. Value of a new automated fluorescence immunoassay (EliA) for PR3 and MPO-ANCA in monitoring disease activity in ANCAassociated systemic vasculitis. Ann N Y Acad Sci, 1050(1): 185–192.
  39. Sperotto F, Seguso M, Gallo N, et al., 2017. Anti-DFS70 antibodies in healthy schoolchildren: a follow-up analysis. Autoimmun Rev, 16(2):210–211. CrossRefGoogle Scholar
  40. Spiera RF, Gordon JK, Mersten JN, et al., 2011. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, singlearm, open-label clinical trial. Ann Rheum Dis, 70(6): 1003–1009. CrossRefGoogle Scholar
  41. Spies-Weisshart B, Schilling K, Böhmer F, et al., 2013. Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graftversus-host disease (GVHD). J Cancer Res Clin Oncol, 139(8):1397–1404. CrossRefGoogle Scholar
  42. Srinivasan M, Flynn R, Price A, et al., 2012. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood, 119(6):1570–1580. CrossRefGoogle Scholar
  43. Svegliati S, Olivieri A, Campelli N, et al., 2007. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood, 110(1):237- 241.
  44. Tyndall A, Dazzi F, 2008. Chronic GVHD as an autoimmune disease. Best Pract Res Clin Haematol, 21(2):281–289. CrossRefGoogle Scholar
  45. Wang KS, Kim HT, Nikiforow S, et al., 2017. Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood, 130(26):2889–2899. CrossRefGoogle Scholar
  46. Watanabe A, Kodera M, Sugiura K, et al., 2004. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum, 50(3):892–900. CrossRefGoogle Scholar
  47. Wesierska-Gadek J, Penner E, Hitchman E, et al., 1992. Nucleolar proteins B23 and C23 as target antigens in chronic graft-versus-host disease. Blood, 79(4):1081–1086.Google Scholar
  48. Zhang AB, Wang Y, Hu C, et al., 2017. Laparoscopic versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a single-center experience. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 18(6):532–538. CrossRefGoogle Scholar

Copyright information

© Zhejiang University and Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.National Health Commission (NHC) Key Laboratory of Combined Multi-organ Transplantation, the First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina
  2. 2.Department of Clinical Laboratory, the Second Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina

Personalised recommendations